Kyle Wood, MD, reviews currently available treatment options for enteric hyperoxaluria and the importance of disease education.
EP. 1: Overview of Hyperoxaluria
Kyle Wood, MD, provides insight on the types of hyperoxaluria, the importance of disease education, and who should be screened for the disease.
EP. 2: Diagnosis of Enteric Hyperoxaluria
An expert endourologist describes the prevalence and diagnostic processes of enteric hyperoxaluria, as well as common challenges faced in making a diagnosis.
EP. 3: Clinical Presentation of Enteric Hyperoxaluria
Kyle Wood, MD, comments on the presenting signs and symptoms of enteric hyperoxaluria and complications of untreated disease.
EP. 4: Treatment Options for Enteric Hyperoxaluria
Kyle Wood, MD, reviews current therapies and strategies for the management of enteric hyperoxaluria.
EP. 5: Challenges with available treatment options for enteric hyperoxaluria
An expert in endourology discusses concerns with currently available treatment options for enteric hyperoxaluria and comments on detecting the disease for patients with recurring stones.
EP. 6: Phase 3 URIROX-1 Trial for Enteric Hyperoxaluria
Kyle Wood, MD, reviews data and clinical implications for the use of reloxaliase in enteric hyperoxaluria as seen in the phase 3 URIROX-1 trial and shares insight on additional ongoing trials.
EP. 7: Unmet Needs for the Treatment of Enteric Hyperoxaluria
Dr. Kyle Wood discusses optimal avenues to increase patient and provider education on enteric hyperoxaluria and provides closing thoughts on the future management of enteric hyperoxaluria.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC